Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.54 |
| ▸ | CTSK | P43235 | 5/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | REN | P00797 | 2/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | PTPRA | P18433 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL843946 | 0.89 | ACE (0.52) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL3644291 | 0.84 | FPR2 (0.49) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL4654386 | 0.83 | CTSS (0.61) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL4654379 | 0.83 | CTSS (0.61) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL1764798 | 0.82 | CTSS (0.64) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL6162474 | 0.82 | CTSS (0.64) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL19969174 | 0.79 | CTSS (0.60) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL18057248 | 0.79 | CTSS (0.60) | CTSSCTSKCTSBCTSLACE | |
| Dl-Phenylalanine SCHEMBL28132478 | 0.79 | ACE (0.61) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL1971863 | 0.79 | CTSS (0.57) | CTSSCTSKCTSBCTSLACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188276-B1 | SUBSTITUTED HYDANTOINS | HOFFMANN LA ROCHE (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-7557221-B2 | Substituted hydantoins | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090048452-A1 | (R)-5-[4-(2-Hydroxy-ethoxy)-phenyl]-3-[(S)-1-(6-iodo-1H-benzoimidazol-2-yl)-2-phenyl-ethyl]-imidazolidine-2,4-dione; map kinase inhibitors; antihyperproliferative agents | CHEN SHAOQING | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048452-A1 | (R)-5-[4-(2-Hydroxy-ethoxy)-phenyl]-3-[(S)-1-(6-iodo-1H-benzoimidazol-2-yl)-2-phenyl-ethyl]-imidazolidine-2,4-dione; map kinase inhibitors; antihyperproliferative agents | MAPK1, MAP3K2, MAP3K1 | CTSS 4429/4885CTSK 3289/4885CTSB 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.